CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 30 enrolled
Drug / intervention
Xanthohumol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03735420
NCT03735420Phase 1Active

Xanthohumol Metabolism and Signature (XMaS) in Healthy Adults

National University of Natural Medicine·interventional·Posted Nov 8, 2018·Updated Aug 27, 2024

In Brief

A Phase 1 clinical trial evaluating Xanthohumol and Placebo oral capsule for Healthy. Active but no longer recruiting, targeting 30 participants across 1 site.

Detailed Summary

A pilot study to assess the safety and tolerability of oral xanthohumol in humans, to identify a biological signature of xanthohumol exposure, and to characterize the role of xanthohumol metabolism by intestinal microorganisms in that signature.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States

Timeline

Phase 1ActiveOverdue
20192020202120222023202420252026
First PostedNov 8, 2018
Enrollment StartAug 12, 2019
Primary CompletionMay 7, 2020
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.6 years ago

Interventions

Xanthohumoldrug

The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.

Placebo oral capsuledrug

The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.